Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

As we tick over into FY26, all eyes are focused on stocks offering strong potential gains or losses over the next 12 months.

At the close of FY25 yesterday, leading winners were healthcare stocks. The S&P/ASX 200 Healthcare Index (ASX: XHJ), jumped 1.58% on Monday, and is up 0.27% as of lunchtime today.

Health insurance provider NIB Holdings Ltd (ASX: NHF) was Monday's best index performer. NIB shares had an exceptional start to the week, shooting 9.43% higher to close at $7.08 per share. The increase followed an optimistic report from ASX broker UBS.

But in its latest note to investors, Macquarie Group appears to hold a different view on the stock.

Today the health insurer's share price has corrected by around 2.26%, falling to $6.92 as of lunchtime.

NIB's share price has had a rollercoaster ride over the past year, rising 25.36% since early January. But the stock suffered a sharp 17.74% drop in late August last year after following its full-year results announcement. Over the year, shares are currently 4.55% lower.

For context, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.14% higher as of lunchtime today.

Here's what Macquarie has to say about NIB in FY26.

shadow of a man looking out a window with arrows signifying falling share price

Image source: Getty Images

Macquarie less confident about NIB shares

The broker has maintained its underperform rating on NIB shares. It cited a cautious outlook off the back of the company's operational and environmental headwinds across multiple divisions.

It has revised its target price on the stock to $5.60, up from $5.55 previously. This would represent a 20.9% decline from yesterday's close and a 19.07% drop from the current trading price.

The broker also expects company earnings to be 1.8% higher for FY25. But, for FY26 it expects a 3.6% decline due to divisional challenges.

In its investor note, Macquarie explained that political and regulatory risk will grow in FY26 as the health minister is given a second term and the NDIS moves into focus.

The broker said it has not included concerns around industry reform into its earning forecast at this stage.

However, it has forecast slight earnings pressure for the company's IIHI (International Inbound Health Insurance) division in FY26. This is largely due to migration trends slow for students, contract pricing comes under pressure, and competition increases across products.

In NIB's New Zealand division, Macquarie notes that while it expects underlying profit to be mostly positive in FY26, appointment of a new division head could create some downside earnings risk for the division. 

"Reshuffling of divisional executives often lead to changes in strategy and earnings rebasing," the note said.

The broker is also keeping a close eye on phoenixing, changes to the price approval process, change to the students deed, and findings of the PALM review. All of these issues could create potential headwinds for the healthcare stock.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »